igm
biosciences
announces
third
quarter
financial
results
provides
corporate
update
mountain
view
globe
newswire
initial
data
phase
trial
relapsed
refractory
lymphoma
presented
american
society
hematology
annual
meeting
exposition
december
clinical
trial
treatment
solid
cancers
lymphoma
initiated
igm
biosciences
nasdaq
igms
biotechnology
company
focused
creating
developing
engineered
igm
antibodies
today
announced
financial
results
third
quarter
ended
september
provided
update
recent
developments
pleased
progress
made
first
three
quarters
advancing
pipeline
programs
clinic
research
said
fred
schwarzer
chief
executive
officer
igm
biosciences
lead
igm
antibodies
moving
forward
clinical
trials
look
forward
presenting
initial
clinical
data
phase
trial
upcoming
ash
annual
meeting
december
presenting
initial
clinical
data
phase
trial
pipeline
updates
phase
data
presented
american
society
hematology
ash
annual
meeting
igm
report
initial
data
phase
clinical
trial
evaluating
patients
relapsed
refractory
lymphoma
nhl
application
igm
engineered
igm
antibody
technology
ash
annual
meeting
held
virtually
december
initiated
phase
trial
igm
announced
first
patient
dosed
phase
clinical
trial
evaluating
patients
solid
cancers
nhl
igm
expects
report
initial
data
phase
trial
preclinical
data
presented
society
immunotherapy
cancer
sitc
annual
meeting
poster
titled
targeting
delivery
expressing
tumors
using
x
cytokine
fusion
igm
enhance
cell
nk
cell
mediated
tumor
cytotoxicity
made
available
online
via
meeting
virtual
poster
hall
beginning
monday
november
et
corporate
updates
antibody
discovery
collaboration
abcellera
announced
igm
abcellera
announced
entered
strategic
research
collaboration
license
agreement
intended
expedite
discovery
novel
igm
antibodies
abcellera
generate
panels
antibodies
multiple
therapeutic
targets
identified
igm
using
antibody
discovery
technology
igm
rights
develop
commercialize
novel
antibodies
resulting
collaboration
third
quarter
financial
results
cash
investments
cash
investments
september
million
compared
million
december
cash
investments
september
million
compared
million
december
research
development
r
expenses
third
quarter
r
expenses
million
compared
million
period
third
quarter
r
expenses
million
compared
million
period
general
administrative
g
expenses
third
quarter
g
expenses
million
compared
million
period
third
quarter
g
expenses
million
compared
million
period
net
loss
third
quarter
net
loss
million
loss
per
share
compared
net
loss
million
loss
per
share
period
third
quarter
net
loss
million
loss
per
share
compared
net
loss
million
loss
per
share
period
shares
outstanding
shares
outstanding
third
quarter
million
compared
million
period
financial
guidance
igm
expects
operating
expenses
approximately
million
excluding
estimated
compensation
expense
approximately
million
including
compensation
expense
igm
estimates
gaap
operating
expenses
million
igm
expects
end
balance
million
cash
investments
igm
biosciences
headquartered
mountain
view
california
igm
biosciences
biotechnology
company
focused
creating
developing
engineered
igm
antibodies
since
igm
biosciences
worked
overcome
manufacturing
protein
engineering
hurdles
limited
therapeutic
use
igm
antibodies
efforts
igm
biosciences
created
proprietary
igm
technology
platform
development
igm
antibodies
clinical
indications
inherent
properties
may
provide
advantages
compared
igg
antibodies
cautionary
note
regarding
statements
press
release
contains
statements
including
statements
relating
igm
plans
expectations
forecasts
future
events
statements
include
limited
potential
expectations
regarding
company
igm
technology
platform
igm
antibodies
statements
regarding
company
phase
clinical
trials
including
timing
reporting
initial
data
clinical
trials
presentation
initial
clinical
data
company
phase
trial
ash
annual
meeting
december
company
development
strategy
potential
expectations
regarding
collaboration
abcellera
nature
scope
collaboration
company
future
financial
operating
performance
including
financial
guidance
full
year
year
end
cash
investments
balance
statements
igm
chief
executive
officer
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
including
limited
potential
delays
disruption
resulting
pandemic
governmental
responses
pandemic
including
future
impacts
igm
operations
manufacturing
product
candidates
progression
clinical
trials
enrollment
current
future
clinical
trials
collaborations
related
efforts
igm
early
stages
clinical
drug
development
risks
related
use
engineered
igm
antibodies
novel
unproven
therapeutic
approach
igm
ability
advance
product
candidates
successfully
complete
clinical
trials
timelines
projects
risk
necessary
regulatory
approvals
obtained
igm
ability
adequately
demonstrate
sufficient
safety
efficacy
product
candidates
igm
ability
enroll
patients
ongoing
future
clinical
trials
potential
clinical
trials
future
clinical
trials
product
candidates
differ
preclinical
preliminary
expected
results
igm
ability
successfully
manufacture
supply
product
candidates
clinical
trials
igm
ability
obtain
additional
capital
finance
operations
needed
uncertainties
related
projections
size
patient
populations
suffering
diseases
igm
targeting
igm
ability
obtain
maintain
protect
intellectual
property
rights
developments
relating
igm
competitors
industry
including
competing
product
candidates
therapies
risks
related
collaborations
third
parties
including
risk
occurrence
event
change
circumstance
could
give
rise
termination
collaboration
general
economic
market
conditions
risks
uncertainties
including
fully
described
igm
filings
securities
exchange
commission
sec
including
igm
annual
report
form
filed
sec
march
igm
quarterly
report
form
filed
sec
november
igm
future
reports
filed
sec
statements
contained
press
release
speak
date
hereof
igm
specifically
disclaims
obligation
update
statement
except
required
law
contact
argot
partners
david
pitts
igmbio
